Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465268 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT02465268: Completed Phase 2 study, sponsored by University of Florida.
NCT02465268 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465268, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
Primary Outcome
Kaplan-Meier survival curves and the log rank test will be used to characterize and compare OS in patients who received pp65-LAMP mRNA DC vaccine (Arms 1 and 2) and in control patients (Arm 3). OS will be defined as the time between first vaccination and death and will be censored at the last follow-up if death has not occurred.
Interventions
- DRUG Saline
- BIOLOGICAL pp65-shLAMP DC with GM-CSF
- BIOLOGICAL unpulsed PBMC and saline
- DRUG Td
- BIOLOGICAL pp65-flLAMP DC with GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2016-08-09 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
What the finished NCT02465268 record still lists
NCT02465268 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 5 interventions - of which Saline is the first listed.
NCT02465268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465268 about?
NCT02465268 is a clinical study titled "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme". The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
What is the current status of trial NCT02465268?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2016-08-09. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT02465268?
The interventions under investigation include: Saline (DRUG), pp65-shLAMP DC with GM-CSF (BIOLOGICAL), unpulsed PBMC and saline (BIOLOGICAL), Td (DRUG), pp65-flLAMP DC with GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465268?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465268's enrollment target sits among peer trials
175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI